Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, CFO | April 20, 2022 | April 22, 2022 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Horizon Therapeutics Public Ltd Co
Report date April 20, 2022 · Filed April 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,049 |
Ending reported balance
After 2022-04-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-20 · Exercise / conversion · Acquired 50,000 · Balance 51,049 Row 2 · 2022-04-20 · Sale · Disposed 28,458 · Balance 22,591 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-20 · Sale · Disposed 21,542 · Balance 1,049 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-22 | Direct | 36,424 |
Reported balance
After 2022-04-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-04-20 · Exercise / conversion · Disposed 50,000 · Balance 36,424 F5: The option is fully vested and exercisable. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy LLC | 66,673 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 66,673 F4: The Reporting Person and his spouse share voting power over the securities held by the LLC. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 72,789 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 72,789 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Reporting Person and his spouse share voting power over the securities held by the LLC.
F5: The option is fully vested and exercisable.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Sagimet Biosciences Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11 | Direct | 39,567 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:22 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001104659-26-074052 · tm2617570-5_4seq1.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,567 Underlying: Series A Common Stock · 39,567 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 21:37 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 32,250 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001104659-25-058221 · tm2517621-2_4seq1.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,250 Underlying: Series A Common Stock · 32,250 shares Expires 2035-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 9,279 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001104659-24-069632 · tm2416701-2_4seq1.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,279 Underlying: Series A Common Stock · 9,279 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 73,014 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001104659-24-043263 · tm2410971-3_4seq1.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,014 Underlying: Series A Common Stock · 73,014 shares Expires 2034-03-31 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following April 1, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:15 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-23-035564 · doc4.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 6,376 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-034178 · doc4.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376 Underlying: Common Stock · 6,376 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 22:47 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-22-025455 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,424 Underlying: Ordinary Shares · 50,000 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 22:47 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 21,542 | $115.17 | $2,480,992.14 |
DisclosureSEC source: 0001209191-22-025455 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 22:47 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 28,458 | $114.36 | $3,254,456.88 |
DisclosureSEC source: 0001209191-22-025455 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,591 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 22:47 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 50,000 | $22.14 | $1,107,000.00 |
DisclosureSEC source: 0001209191-22-025455 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 185,060 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · derivative · entry 7 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,424 Underlying: Ordinary Shares · 185,060 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,275 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,275 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 91,710 | $110.01 | $10,089,026.27 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 66,673 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 215,335 | $110.01 | $23,688,788.02 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 185,060 | $22.14 | $4,097,228.40 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 30,275 | $15.96 | $483,189.00 |
DisclosureSEC source: 0001209191-22-023845 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 663 | $110.00 | $72,930.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 9 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 158,383 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021. F1 · ownership.nature: These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,481 | $110.00 | $162,910.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 8 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 159,046 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021. F1 · ownership.nature: These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,090 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · derivative · entry 10 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,275 Underlying: Ordinary Shares · 26,090 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 11,699 | $110.01 | $1,287,017.52 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 7 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 160,527 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.115 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 26,090 | $110.00 | $2,870,001.75 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.115 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 26,090 | $15.96 | $416,396.40 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 172,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 172,226 F1 · ownership.nature: These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. Read SEC document |
| March 07, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 172,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 72,789 Read SEC document |
| March 07, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 66,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 245,015 Read SEC document |
| March 07, 2022 Filed Mar 25, 2022 22:38 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 66,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021151 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 5,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004633 · doc4.xml · derivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,558 shares Expires 2022-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,463 | $86.42 | $212,852.46 |
DisclosureSEC source: 0001209191-22-004633 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,675 Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 5,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004633 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:58 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001209191-22-004627 · doc4.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in equal monthly installments over a three-year period. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 10 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,286 Underlying: Ordinary Shares · 11,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F8 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2021. F8 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2021. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 11,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 9 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 Underlying: Ordinary Shares · 11,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F7 · derivative.exercise_date: Two-thirds of the ordinary shares subject to the RSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F7 · derivative.expiration_date: Two-thirds of the ordinary shares subject to the RSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 11,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 8 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,069 Underlying: Ordinary Shares · 11,067 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 50% of the shares subject to the RSU's vested on 1/5/2022, and the remaining shares vest on 1/5/2023. F6 · derivative.expiration_date: 50% of the shares subject to the RSU's vested on 1/5/2022, and the remaining shares vest on 1/5/2023. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 14,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 7 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,514 Underlying: Ordinary Shares · 14,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,983 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 50,666 | $101.84 | $5,159,825.44 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,580 Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 47,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,246 F2 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2022, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 66,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 01:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 9,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002291 · doc4.xml · derivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,522 Underlying: Ordinary Shares · 9,522 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,575 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,365 Underlying: Ordinary Shares · 8,575 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 8,575 | $110.00 | $943,250.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · nonDerivative · entry 5 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 8,575 | $15.96 | $136,857.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · nonDerivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 1,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · nonDerivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049 Read SEC document |
| August 25, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 178,389 Read SEC document |
| August 25, 2021 Filed Dec 31, 2021 02:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GiftOrdinary Shares | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071650 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 17,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048788 · doc4.xml · derivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,418 Underlying: Ordinary Shares · 17,418 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,858 | $102.50 | $395,445.00 |
DisclosureSEC source: 0001209191-21-048788 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,261 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 8,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048788 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,119 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F2 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program. Read SEC document |
| May 14, 2021 Filed May 14, 2021 22:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 102,925 | $90.01 | $9,263,846.97 |
DisclosureSEC source: 0001209191-21-032882 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 172,226 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 17,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012407 · doc4.xml · derivative · entry 6 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,416 Underlying: Ordinary Shares · 17,416 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.